Skip to main content

Galectin Therapeutics Inc.

corporate_fare Company Profile

Galectin Therapeutics Inc.

GALT·NASDAQ·Life Sciences·CIK 0001133416

GALECTIN THERAPEUTICS INC is a clinical-stage biopharmaceutical company focused on drug research and development for fibrotic disease, cancer, and other selected diseases. The company's drug candidates target galectin proteins, which are central to biological and pathological functions. They manufacture proprietary, patented complex carbohydrates from naturally occurring plant products. These carbohydrate molecules are formulated into pharmaceutical preparations. Using these unique carbohydrate-based compounds, which primarily bind to and inhibit galectin proteins, especially galectin-3, the company develops therapies for diseases where galectin proteins play a role in disease development. They concentrate on serious, life-threatening diseases with limited current treatment options, specifically metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with cirrhosis and certain cancer indications. The company's lead galectin-3 inhibitor is belapectin (GR-MD-02). Preclinical models have shown belapectin can reverse liver fibrosis and cirrhosis, and clinical studies have demonstrated its ability to decrease portal hypertension and prevent the development of esophageal varices. Belapectin has potential for treating various diseases due to galectin-3's involvement in multiple biological pathways, including fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis. Experimental evidence supports galectin-3's role in fibrosis; animals lacking the galectin-3 gene cannot develop fibrosis in response to experimental stimuli, unlike those with an intact gene. GALECTIN THERAPEUTICS INC is using its galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in MASH patients.

Galectin Therapeutics Inc. (NASDAQ:GALT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for GALT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for GALT spans 10-Q, DEF 14A, PRE 14A, 8-K.

Recent high-impact activity:

  • Galectin Narrows Q3 Loss to $3.6M as Phase 3 Protocol Sits With FDA
  • Galectin 10-Q: Going Concern Warning, Cash Funds Operations Only Through June 2027
  • Galectin Therapeutics Seeks Shareholder Approval to Double Authorized Shares to 250M
  • Galectin Seeks Shareholder Nod to Nearly Double Authorized Shares to 250M
  • Galectin Posts Wider Q2 Loss but Advances Belapectin Toward Phase 3

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$30.84M
Diluted EPS
-$0.48
Op. Cash Flow
-$23.88M
Operating Income
-$20.09M
Cash & Equivalents
$17.72M
Debt / Equity
0.00×
Shares Outstanding
65.2M sh
Source: 10-K · filed 2026-03-31 · accession 0001140361-26-012155

Short Interest & Short Volume

46.26 days to cover

FINRA reported short interest of 8,975,877 shares in GALT as of the October 30, 2026 settlement, a 1.7% decrease from the prior period — about 46.3 days to cover at its recent average daily volume. On November 20, 2026, 57.7% of GALT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,975,877 shares as of October 30, 2026
Change vs prior period▼ 1.7%
Days to cover46.26 at avg daily volume of 194,017
Daily short volume (FINRA facilities)57.7% of 79,766 shares on November 20, 2026
5-day average short volume48.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for GALT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-04.

Debt-to-Equity Conversion · Balance Sheet Transformation

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with G →
$2.57 -4.53% today
52-week range · as of 2026-11-16 $2.02 – $7.13
Market cap
$271.35M
Volume
257.9K (1.3× avg)
3-mo avg 204.5K
Live data · 2026-11-21 18:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GALT - Latest Insights

GALT
Nov 16, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $2.57 info
Change: -$0.5318 (-17%) info
Market Cap: $271.354M info
GALT
Nov 16, 2026, 7:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $2.57 info
Change: -$0.5318 (-17%) info
Market Cap: $271.354M info
GALT
Oct 13, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.94
Real-time Price: $2.57 info
Change: -$1.37 (-35%) info
Market Cap: $271.354M info
GALT
Oct 02, 2026, 3:53 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $2.57 info
Change: -$1.35 (-34%) info
Market Cap: $271.354M info
GALT
Aug 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.57 info
Change: -$0.8818 (-26%) info
Market Cap: $271.354M info
GALT
Aug 14, 2026, 7:55 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.49
Real-time Price: $2.57 info
Change: -$0.9218 (-26%) info
Market Cap: $271.354M info
GALT
Aug 04, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.21
Real-time Price: $2.57 info
Change: -$0.6418 (-20%) info
Market Cap: $271.354M info
GALT
Aug 04, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $2.57 info
Change: -$0.4918 (-16%) info
Market Cap: $271.354M info
GALT
Jun 23, 2026, 7:53 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $2.57 info
Change: -$0.2018 (-7%) info
Market Cap: $271.354M info
GALT
Jun 23, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.77
Real-time Price: $2.57 info
Change: -$0.2018 (-7%) info
Market Cap: $271.354M info
GALT
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.72
Real-time Price: $2.57 info
Change: -$0.1518 (-6%) info
Market Cap: $271.354M info
GALT
May 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.31
Real-time Price: $2.57 info
Change: +$0.2582 (+11%) info
Market Cap: $271.354M info
GALT
May 15, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.30
Real-time Price: $2.57 info
Change: +$0.2682 (+12%) info
Market Cap: $271.354M info
GALT
Mar 31, 2026, 4:11 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $2.79
Real-time Price: $2.57 info
Change: -$0.2218 (-8%) info
Market Cap: $271.354M info
GALT
Mar 31, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.57
Real-time Price: $2.57 info
Change: -$0.0018 (-0.07%) info
Market Cap: $271.354M info
GALT
Mar 31, 2026, 7:50 AM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $2.57 info
Change: -$0.0018 (-0.07%) info
Market Cap: $271.354M info
GALT
Mar 17, 2026, 7:50 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.18
Real-time Price: $2.57 info
Change: -$0.6118 (-19%) info
Market Cap: $271.354M info
GALT
Jan 06, 2026, 11:10 AM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $3.79
Real-time Price: $2.57 info
Change: -$1.22 (-32%) info
Market Cap: $271.354M info
GALT
Jan 02, 2026, 8:27 AM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $2.57 info
Change: -$1.55 (-38%) info
Market Cap: $271.354M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets